Coya Therapeutics, Inc.
COYA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,564 | $164 | $258 | $2 |
| % Growth | 2,078.4% | -36.6% | 13,111.3% | – |
| Cost of Goods Sold | $7 | $7 | $5,214 | $1,937 |
| Gross Profit | $3,557 | $157 | -$4,956 | -$1,935 |
| % Margin | 99.8% | 95.8% | -1,921.9% | -99,154.1% |
| R&D Expenses | $2,917 | $3,663,103 | $5,214 | $1,937 |
| G&A Expenses | $0 | $2,908,191 | $2,714 | $2,138 |
| SG&A Expenses | $2,557 | $2,908,191 | $2,714 | $2,138 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$6,564,723 | -$5,207 | -$1,931 |
| Operating Expenses | $5,474 | $6,571 | $2,721 | $2,145 |
| Operating Income | -$1,917 | -$6,415 | -$7,677 | -$4,080 |
| % Margin | -53.8% | -3,920.5% | -2,976.9% | -209,031.5% |
| Other Income/Exp. Net | -$199 | $320 | $370 | $444 |
| Pre-Tax Income | -$2,116 | -$6,095 | -$7,307 | -$3,636 |
| Tax Expense | $0 | $0 | $0 | -$720 |
| Net Income | -$2,116 | -$6,095 | -$7,307 | -$2,916 |
| % Margin | -59.4% | -3,725.2% | -2,833.4% | -149,373.8% |
| EPS | -0.13 | -0.36 | -0.44 | -0.18 |
| % Growth | 63.9% | 18.2% | -144.4% | – |
| EPS Diluted | -0.13 | -0.36 | -0.44 | -0.18 |
| Weighted Avg Shares Out | 16,733 | 16,725 | 16,721 | 16,357 |
| Weighted Avg Shares Out Dil | 16,733 | 16,725 | 16,721 | 16,357 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $7 | $7 | $7 | $7 |
| EBITDA | -$2,109 | -$6,088 | -$7,670 | -$4,073 |
| % Margin | -59.2% | -3,721% | -2,974.2% | -208,681.1% |